The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors

The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwo, Paul Y., Vinayek, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Society of Pancreatobiliary Diseases 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240782/
https://www.ncbi.nlm.nih.gov/pubmed/22195237
http://dx.doi.org/10.5009/gnl.2011.5.4.406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240782/
https://www.ncbi.nlm.nih.gov/pubmed/22195237
http://dx.doi.org/10.5009/gnl.2011.5.4.406

Ejemplares similares